Summary of Key Points Core Viewpoint - The Hong Kong biotechnology sector experienced a significant decline, with most stocks falling sharply, indicating a bearish trend in the market [1]. Company Performance - **Gilead Sciences (歌礼制药-B)**: Decreased by 15.06%, latest price at 15.510, market cap at 14.946 billion [2]. - **Yunkang Group (云康集团)**: Fell by 14.18%, latest price at 2.300, market cap at 1.429 billion [2]. - **PAG Pharmaceuticals (派格生物医药-B)**: Dropped by 9.15%, latest price at 31.760, market cap at 12.258 billion [2]. - **Tengsheng Boao (腾盛博药-B)**: Declined by 8.30%, latest price at 2.210, market cap at 1.590 billion [2]. - **China Antibody (中国抗体-B)**: Decreased by 7.49%, latest price at 3.210, market cap at 4.371 billion [2]. - **Jiahua Biotech (嘉和生物-B)**: Fell by 7.08%, latest price at 4.460, market cap at 2.347 billion [2]. - **Sillod Pharmaceuticals (思路迪医药股份)**: Dropped by 6.06%, latest price at 7.910, market cap at 2.042 billion [2]. - **Tiger Med (泰格医药)**: Decreased by 5.73%, latest price at 54.250, market cap at 46.711 billion [2]. - **Kangji Medical (加科思-B)**: Fell by 5.69%, latest price at 8.120, market cap at 6.404 billion [2]. - **WuXi AppTec (药明巨诺-B)**: Dropped by 5.14%, latest price at 5.720, market cap at 2.382 billion [2]. - **Three Leaf Clover Biotech (三叶草生物-B)**: Decreased by 5.13%, latest price at 0.740, market cap at 0.960 billion [2]. - **Yiming Oncology (宜明昂科-B)**: Fell by 4.76%, latest price at 12.810, market cap at 5.218 billion [2]. - **Junshi Biosciences (君实生物)**: Decreased by 4.69%, latest price at 34.540, market cap at 35.462 billion [2]. - **Zhonghui Biotech (中慧生物-B)**: Fell by 4.39%, latest price at 51.150, market cap at 20.125 billion [2]. - **Zhaoyan New Drug (昭衍新药)**: Decreased by 4.38%, latest price at 23.140, market cap at 17.343 billion [2].

格隆汇8月18日丨中国抗体-B(03681.HK)公布，公司将于2025年8月29日召开董事会会议，以（其中包 括）审议及通过集团截至2025年6月30日止六个月的中期业绩及其发布。 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或 任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 於 本 公 告 日 期 ， 本 公 司 執 行 董 事 為 梁 瑞 安 博 士 ， 本 公 司 非 執 行 董 事 為 陳 海 剛 博 士、董汛先生、王小素女士及張健民博士，以及本公司獨立非執行董事為George William Hunter CAUTHERLEY先生、韓炳祖先生、李志明博士、李之秀女士及申楠 先生。 中國抗體製藥有限公司 執行董事、主席兼首席執行官 梁瑞安博士 香港，二零二五年八月十八日 SinoMab BioScience Limited 中 國 抗 體 製 藥 有 限 公 司 （於香港註冊成立的有限公司） （股份代號：3681） 董事會會議召開日期 中國抗體製藥有限公司（「本公司」及其附屬公司「本集團」）董事會（「董事會」）兹通 告謹定於二零二五年八月二十九日（ 星期五 ）舉行董事會會議，以考慮及通過本集 團截至二零二 ...

智通财经APP讯，中国抗体-B(03681)发布公告，于2025年8月15日根据认购协议发行1.57亿股认购股份 予认购人。 ...

Group 1 - The company China Antibody-B (03681) announced the issuance of 157 million subscription shares to the subscribers based on the subscription agreement on August 15, 2025 [1]

翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 中國抗體製藥有限公司 FF305 呈交日期： 2025年8月15日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 普通股 | 證券代號 (如上市) | 03681 | 說明 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | | | 事件 | 佔有關事件前的現有已發 | 每股發行/出售價 (註4) | 已發行股份總數 | ...

（於香港註冊成立的有限公司） （股份代號：3681） 根據一般授權認購新股份 — 個別完成 董事會欣然宣佈，由於認購協議所載先決條件已獲達成，若干認購事項已根據 各相關認購協議的條款及條件於二零二五年八月十五日完成。 緒言 茲提述中國抗體製藥有限公司（「本公司」）日期為二零二五年七月二十二日的公告 （「該公告」），內容有關根據一般授權認購本公司新股份。除另有所指外，本公告 所用詞彙與該公告所界定者具有相同涵義。除認購人的名稱及詳情外，每份認購 協議的條款相同。 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或 任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 SinoMab BioScience Limited 中 國 抗 體 製 藥 有 限 公 司 完成個別認購新股份 董事會欣然宣佈，由於認購協議所載先決條件已獲達成，惟(i)本公司與認購人H 及(ii)本公司與認購人O的認購事項除外，故根據各相關認購協議的條款及條件， 二十 一(21) ...

截至2024年年报，中国抗体-B营业总收入202.6万元、净利润-1.85亿元。 8月15日，中国抗体-B(03681)盘中上涨9.57%，截至14:56，报3.55元/股，成交1.38亿元。 中国抗体制药有限公司专注于研发、生产和商业化基于单克隆抗体的生物制剂来治疗免疫性疾病，其中 旗舰产品SM03 (Suciraslimab) 是全球首款用于治疗类风湿关节炎的抗CD22单抗药物，正在全速进行商 业化进程。公司的其他关键数据包括2023年4月其SM03 (Suciraslimab)在中国进行治疗类风湿关节炎的 III期临床研究完成，并且在同年9月5日获得国家药品监督管理局接受其治疗类风湿关节炎的生物制品许 可申请，其生产基地在2024年1月完成了临床现场检查和生产质量管理规范检查。 本文源自：金融界 作者：行情君 ...

Core Viewpoint - China Antibody-B (03681) has seen a significant stock price increase, rising over 11% during trading, with a current price of 3.52 HKD and a trading volume of 106 million HKD, following the announcement of a strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute [1] Group 1: Strategic Cooperation - The company announced a three-year comprehensive strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute, aimed at joint research and development in the biomedical field [1] - The board believes that the cooperation agreement provides valuable opportunities for both parties to leverage their resources and expertise, achieving mutual benefits and synergies [1] - The cooperation is designed to accelerate the development of innovative drugs and promote the translation of research results into clinical applications globally [1] Group 2: Project-Driven Model - The collaboration will adopt a project-driven model, focusing on resource sharing and efficient communication as its core framework [1] - This model allows the company to directly utilize the advanced laboratory facilities, experimental animal supply resources (especially non-primate animals), and valuable data assets of Sun Yat-sen University Hong Kong Advanced Institute, which are critical for driving innovation in drug research and sustainable development [1] - The board views this strategic cooperation as a framework for mutual benefit, contributing to growth and ensuring long-term sustainability, aligning with the company's strategy to advance its pipeline of innovative drugs [1]

Core Viewpoint - China Antibody-B (03681) has seen a significant stock price increase, rising over 11% during trading, with a current price of 3.52 HKD and a trading volume of 106 million HKD, following the announcement of a strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute [1] Group 1: Strategic Cooperation - The company announced a three-year strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute, aimed at joint research and development in the biomedical field [1] - The board believes that the cooperation agreement provides valuable opportunities for both parties to leverage their resources and expertise, achieving mutual benefits and synergies [1] - The collaboration is designed to accelerate the development of innovative drugs and promote the translation of research results into clinical applications globally [1] Group 2: Project-Driven Model - The cooperation will adopt a project-driven model, focusing on resource sharing and efficient communication as its core framework [1] - This model allows the company to directly utilize the advanced laboratory facilities, experimental animal supply resources (especially non-primate animals), and valuable data assets of Sun Yat-sen University Hong Kong Advanced Institute, which are critical for driving innovation in drug research and sustainable development [1] - The board views this strategic partnership as a framework for mutual benefit, contributing to growth and ensuring long-term sustainability [1]